Abcam Expects 23% Revenue Growth In H1 2022

Shares of Abcam plc (ABCM) have lost 35% of their value year-to-date and trade around $15.

The Cambridge, UK-based Abcam is a global life sciences company providing validated antibodies and biological tools to the scientific community. Its customers are primarily scientists and researchers in academic institutions, research institutes, and pharmaceutical, biotechnology and diagnostics companies.

The company is slated to report its full financial results for the six months ended June 30, 2022 on Sep.12.

Total revenues for the six-month period are expected to be approximately 185 million pounds compared to 150.2 million pounds in the year-ago period, implying a growth of 23%.

For full-year 2022, Abcam anticipates revenue to increase 20% over the prior year. Revenue was 315.4 million pounds in 2021.

ABCM has traded in a range of $12.54 to $24.00 in the last 1 year. The stock closed Wednesday's trading at $15.25, up 3.88%.

For comments and feedback contact: editorial@rttnews.com

Follow RTT